With $2B J&J Deal, FCA Proves It's Still The Anti-Fraud King

By Greg Ryan (November 4, 2013, 8:51 PM EST) -- The U.S. Department of Justice's $2.2 billion settlement with Johnson & Johnson shows that, despite the recent attention heaped on whistleblower provisions in Dodd-Frank and similar laws, the False Claims Act remains the federal government's weapon of choice in extracting gargantuan settlements from companies that have allegedly committed fraud.

Announced Monday morning, the agreement resolves FCA claims that Johnson & Johnson promoted the antipsychotic drug Risperdal and two other medications for off-label uses and paid kickbacks to physicians and a large pharmacy provider.

The settlement is one of the largest in U.S. history involving health care fraud, but it is by no...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!